(redirected from cathepsin)
Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
Related to cathepsin: Cathepsin C
CTSCClinical and Translational Science Center (University of California at Davis)
CTSCChenega Technology Services Corporation
CTSCCanadian Technical Security Conference (Burlington, ON, Canada)
CTSCCommunity Treatment and Services Center
CTSCComputerized Test of Self-Control
CTSCClustered Tunnel Server Configuration
CTSCCountrywide Tax Service Corporation
CTSCCarlton Trail Ski Club (Canada)
References in periodicals archive ?
We recently published evidence that high serum concentrations of the cysteine proteases cathepsins B and H are of prognostic importance in predicting the rate of death in colorectal (6) and melanoma cancer (7).
Cathepsin S is a member of the cysteine protease family of cathepsin inhibitors that catalyzes proteolytic cleavage of membrane-bound fractalkine from the surface of neurons to release soluble fractalkine.
Abstract # 1030; Oral Session 05: New Approaches to Osteoporosis Treatment (Preclinical), September 17, 2011, 10:45 - 11:00 AM PT - Efficacy of the combination regimens of the cathepsin K inhibitor odanacatib versus alendronate with parathyroid hormone in estrogen-deficient rabbits
VBY-825 is a member of a series of highly potent, spectrum-selective cathepsin inhibitors with structural diversity, which is being developed by Virobay.
Cathepsins are well known biomarkers in a range of diseases, including atherosclerosis, oncology, pulmonary pathologies, and arthritis.
The second imaging agent to be profiled at the AACR Annual Meeting, Cat B 750 FAST, utilizes VisEn's FAST activatable agent platform to target Cathepsin (Cat) B, a lysosomal cysteine protease highly over-expressed in cancers and premalignant lesions and associated with cancer growth, neo-vascularization and metastasis.
Other secondary endpoints included change from baseline in biochemical markers of bone resorption (s-CTX, u-NTx, u-DPyr), bone formation (s-BSAP, s-P1NP), other markers of osteoclast number (s-TRAP-5b) and cathepsin K activity (s-1CTP).
a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat-K FAST(TM) imaging agent for measuring and monitoring Cathepsin K activity associated with disease progression and therapeutic response in vivo.
This molecule is a cathepsin K inhibitor, designed to treat skeletal disorders such as osteoporosis and osteoarthritis.
Doing this the researchers were able to detect fibrin - a protein that causes clots to form, and cathepsin B, an enzyme found in the most dangerous plaques.
A sampling of topics includes BMP signaling and skeletogenesis; the regulation of cathepsin K gene expression; and bone destruction in multiple myeloma.